{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:46:49Z","timestamp":1753890409049,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Exercise-induced anaphylaxis (EIA) is a rare and potentially life-threatening disorder. In difficult to control and refractory cases of EIA, biologics such as omalizumab and dupilumab have shown promise, with documented successful outcomes. Here, we present a case of EIA with lipid transfer protein (LTP) sensitization successfully treated with omalizumab with long-term follow-up. A 12-year-old girl presented to our allergy department because of recurrent episodes of EIA, with no specific food ingestion before exercise. Allergen testing revealed sensitization to weed pollens, particularly mugwort (76.1\u2005kUA\/L) and <jats:italic>Alternaria alternata<\/jats:italic> (10.8\u2005kUA\/L). Allergen component testing indicated sensitization to LTP components from mugwort Art v 3 (49.9\u2005kUA\/L), wheat Tri a 14 (2.03\u2005kUA\/L), and peach Pru p 3 (11.5\u2005kUA\/L), with a negative result for omega-5 gliadin. Despite initial prophylactic treatment with budesonide\u2013formoterol (80\/4.5\u2005\u03bcg) and cetirizine (10\u2005mg) before exercise, the patient still experienced EIA; she was then recommended for dupilumab therapy (an initial dose of 600\u2005mg, followed by 300\u2005mg every 2 weeks for six doses). However, even while undergoing dupilumab therapy, she suffered two anaphylactic episodes after running 800\u20131,000\u2005m. With the patient's consent, a trial of omalizumab was initiated (injections of 300\u2005mg every 4 weeks). After 2\u2005months of omalizumab therapy, the patient showed significant improvement. She had been engaging in physical exercise three times a week and experienced a mild episode of urticaria. There were no further episodes of anaphylaxis or emergency room visits. By the fourth month of omalizumab treatment, she was able to consume food normally even just before exercising and had returned to her full activity level without any restrictions. This case presents the first successful off-label use of omalizumab in the prevention of EIA in the Chinese population. It is concluded that omalizumab may be helpful in resolving EIA symptoms, as evidenced by this case of successful long-term use.<\/jats:p>","DOI":"10.3389\/falgy.2024.1453873","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:10:20Z","timestamp":1726722620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The management of exercise-induced anaphylaxis in a Chinese child with biologics: a case report"],"prefix":"10.3389","volume":"5","author":[{"given":"Nannan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11882-018-0830-6","article-title":"Exercise-induced anaphylaxis: literature review and recent updates","volume":"18","author":"Giannetti","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaip.2016.11.022","article-title":"Food-dependent, exercise-induced anaphylaxis: diagnosis and management in the outpatient setting","volume":"5","author":"Feldweg","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/ddg.15162","article-title":"Wheat-dependent exercise-induced anaphylaxis: subtypes, diagnosis, and management","volume":"21","author":"Faihs","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1111\/cea.12011","article-title":"Lipid transfer proteins: the most frequent sensitizer in Italian subjects with food-dependent exercise-induced anaphylaxis","volume":"42","author":"Romano","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/all.14689","article-title":"Food-dependent NSAID-induced hypersensitivity (FDNIH) reactions: unraveling the clinical features and risk factors","volume":"76","author":"S\u00e1nchez-L\u00f3pez","year":"2021","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaip.2014.10.010","article-title":"The use of anti-IgE therapy beyond allergic asthma","volume":"3","author":"Stokes","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: a review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jaip.2016.09.035","article-title":"Successful treatment with omalizumab in challenge confirmed exercise-induced anaphylaxis","volume":"5","author":"Christensen","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.anai.2012.07.021","article-title":"Successful treatment of exercise-induced anaphylaxis with omalizumab","volume":"109","author":"Bray","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2500\/ar.2017.8.0204","article-title":"Long-term omalizumab use in the treatment of exercise-induced anaphylaxis","volume":"8","author":"Peterson","year":"2017","journal-title":"Allergy Rhinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1228495","DOI":"10.3389\/falgy.2023.1228495","article-title":"Severe exercise-induced anaphylaxis in a hot and humid area successfully treated with omalizumab: a case report","volume":"4","author":"Mobayed","year":"2023","journal-title":"Front Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.18176\/jiaci.0840","article-title":"Effect of dupilumab in a patient with severe asthma complicated with recurrent anaphylaxis: a case report","volume":"33","author":"Otani","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.24920\/004208","article-title":"Dupilumab for treatment of food-dependent, exercise-induced anaphylaxis: report of one case","volume":"38","author":"Zhu","year":"2023","journal-title":"Chin Med Sci J"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1453873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:10:22Z","timestamp":1726722622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1453873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":13,"alternative-id":["10.3389\/falgy.2024.1453873"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1453873","relation":{},"ISSN":["2673-6101"],"issn-type":[{"type":"electronic","value":"2673-6101"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1453873"}}